Company Profile
Clene Inc. Stock Price, News & Analysis
- Ticker:
- CLNN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.34 USD (-0.74%)
Close
Last updated: August 6, 2026
75M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CLNN closed down 0.74% at $5.34. No new same-company headline was identified in the current news window.
Company overview
Late-Stage Neurodegenerative Disease Company
Clene is a late clinical-stage biopharmaceutical company developing therapies that improve mitochondrial health and preserve neurological function in diseases including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.
CNM-Au8 Mechanism
CNM-Au8 is a first-in-class oral suspension of gold nanocrystals designed to improve cellular energy production and utilization, support mitochondrial function and the NAD pathway, reduce oxidative stress, and restore or protect central nervous system cells.
Accelerated Approval Path in ALS
Following a Type C meeting, the FDA indicated that the proposed evidence may support submission and review of an NDA for CNM-Au8 in ALS under the Accelerated Approval pathway. The package centers on reductions in neurofilament light and the relationship between that biomarker response and clinical benefit, particularly survival.
Biomarker-Led Regulatory Strategy
Clene is using neurofilament light as a marker of neuroaxonal injury and treatment effect. The regulatory case depends on demonstrating that biomarker reductions are reasonably likely to predict clinical benefit and are supported by survival observations across the CNM-Au8 dataset.
Broader Neurodegeneration Platform
The mitochondrial and cellular-energy mechanism underlying CNM-Au8 is also being explored in multiple sclerosis and Parkinson’s disease. ALS is the lead regulatory opportunity, while the broader pipeline tests whether the same mechanism can support several neurodegenerative conditions.
Future catalysts
An NDA for CNM-Au8 in ALS is expected to be submitted under the Accelerated Approval pathway in the third quarter of 2026.
The confirmatory Phase 3 RESTORE-ALS study is planned to begin in the first quarter of 2027, with survival improvement as the primary endpoint.
Recent news
- 01
Clene to Present at The Canaccord 46th Annual Growth Conference
Source: Clene Inc.
- 02
- 03
Clene Announces $7 Million Underwritten Offering of Common Stock
Source: Clene Inc.
- 04
Clene to Present at Upcoming May Conferences
Source: Clene Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Clene Inc. (CLNN)?
Clene Inc. (CLNN) most recently closed at 5.34 USD, a -0.74% move versus the previous session.
What is the market cap of Clene Inc. (CLNN)?
Clene Inc. currently has a market capitalization of 75M USD on BioPharmSignal.
What does Clene Inc. do?
Late-Stage Neurodegenerative Disease Company Clene is a late clinical-stage biopharmaceutical company developing therapies that improve mitochondrial health and preserve neurological function in diseases including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8 Mechanism CNM-Au8 is a first-in-class oral suspension of gold...
On which exchange is CLNN stock listed?
Clene Inc. (CLNN) is associated with NASDAQ, United States, Biopharma.
What is RESTORE-ALS?
The confirmatory Phase 3 RESTORE-ALS study is planned to begin in the first quarter of 2027, with survival improvement as the primary endpoint.
Which conditions is Clene Inc. targeting with RESTORE-ALS?
The confirmatory Phase 3 RESTORE-ALS study is planned to begin in the first quarter of 2027, with survival improvement as the primary endpoint.
How does Clene Inc. describe recent progress with RESTORE-ALS?
The confirmatory Phase 3 RESTORE-ALS study is planned to begin in the first quarter of 2027, with survival improvement as the primary endpoint.
What is Late-Stage?
Late-Stage Neurodegenerative Disease Company Clene is a late clinical-stage biopharmaceutical company developing therapies that improve mitochondrial health and preserve neurological function in diseases including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.